Anti-Cancer Drugs

Skip Navigation LinksHome > February 2010 - Volume 21 - Issue 2 > Pulmonary toxicities of biologics: a review
Text sizing:
Anti-Cancer Drugs:
doi: 10.1097/CAD.0b013e328333d662
Review Articles

Pulmonary toxicities of biologics: a review

Peerzada, Maajid Mumtaza; Spiro, Timothy P.b; Daw, Hamed A.b

Collapse Box


With the advancement of research in cancer treatment more and more drugs are being introduced for the treatment of cancer. In this review study, we have tried to look at some of the relatively newly introduced drugs, commonly referred to as biologics. The aim of this study was to review the very rare but fatal pulmonary toxicities (mostly interstitial lung disease) caused by these drugs. The drugs that were reviewed are rituximab, cetuximab, bevacizumab, alemtuzumab, and trastuzumab. This review basically aims at presenting a basic introduction (mechanism of action and indications of use) of these drugs followed by a summary of the incidence, various clinical presentations, diagnosis, treatment options, and outcome of patients around the world who presented with pulmonary toxicities caused by these drugs.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.